Loading...
Dernières publications
-
Dylan Moutachi, Janek Hyzewicz, Pauline Roy, Mégane Lemaitre, Damien Bachasson, et al.. Treadmill running and mechanical overloading improved the strength of the plantaris muscle in the dystrophin‐desmin double knockout (DKO) mouse. The Journal of Physiology, In press, ⟨10.1113/JP286425⟩. ⟨hal-04643936⟩
-
-
Medhi Hassani, Dylan Moutachi, Mégane Lemaitre, Alexis Boulinguiez, Denis Furling, et al.. Beneficial effects of resistance training on both mild and severe mouse dystrophic muscle function as a preclinical option for Duchenne muscular dystrophy. PLoS ONE, 2024, 19, ⟨10.1371/journal.pone.0295700⟩. ⟨hal-04501283⟩
-
Antonio Atalaia, Dagmar Wandrei, Nawel Lalout, Rachel Thompson, Adrian Tassoni, et al.. EURO-NMD registry: federated FAIR infrastructure, innovative technologies and concepts of a patient-centred registry for rare neuromuscular disorders. Orphanet Journal of Rare Diseases, 2024, 19 (1), pp.66. ⟨10.1186/s13023-024-03059-3⟩. ⟨hal-04460667⟩
-
-
-
Florent Porquet, Lin Weidong, Kévin Jehasse, Hélène Gazon, Maria Kondili, et al.. Specific DMPK-promoter targeting by CRISPRi reverses myotonic dystrophy type 1-associated defects in patient muscle cells. Molecular Therapy - Nucleic Acids, 2023, 32, pp.857 - 871. ⟨10.1016/j.omtn.2023.05.007⟩. ⟨hal-04287597⟩
-
Caroline Le Guiner, T Larcher, A Lafoux, G Toumaniantz, S Webb, et al.. Characterization of the muscular and cardiac diseases of the DMSXL mouse model, a transgenic mouse model for Myotonic Dystrophy type 1. American Society of Gene & Cell Therapy, May 2023, LOS ANGELES, United States. ⟨hal-04096181⟩
-
-
Dylan Moutachi, Mégane Lemaitre, Clément Delacroix, Onnik Agbulut, Denis Furling, et al.. Valproic acid reduces muscle susceptibility to contraction‐induced functional loss but increases weakness in two murine models of Duchenne muscular dystrophy. Clinical and Experimental Pharmacology and Physiology, In press, ⟨10.1111/1440-1681.13804⟩. ⟨hal-04146953⟩
Chiffres clés
145
Publications avec texte intégral
Open Access
53 %
Mots clés
Myotonic Dystrophy type 1
Central nervous system
DM1
Transgenic mouse model
Oligodendrocyte
ACETYLCHOLINESTERASE
Animals
RNA interference
Dilated cardiomyopathy
Exercise
Brain dysfunction
Heart failure
Acetylcholinesterase deficiency
Humans
ARN
BIOLOGIE MOLECULAIRE
KNOCKOUT MICE
Quantitative microdialysis
Glucocorticoid-receptor
Muscle
Motoneuron
Endurance training
Transcriptomics
Cells
Myotonic Dystrophy
Transgenic mouse
Expression
Aging
Glucocorticoids
Mouse model
Myotonic dystrophy mouse models
Hypoxia
Glial cells
Cultured
Alternative splicing
Neuron
Trinucleotide repeat expansion
Dystrophie Myotonique
Cell model
Maximal force
Centronuclear myopathy
Skeletal muscle
CONGENITAL MYATHENIC SYNDROME
RNA biology
Fibrosis
PacBio
AAV
Mouse models
CRISPRi
CMS
Intermediate filament
Cell culture model
Desmin
Duchenne muscular dystrophy
Long read sequencing
Thérapie génique
MBNL
Diaphragm
Myotonic dystrophy
Brain
CTG repeat instability
Antisense oligonucleotide
PCR
Therapy
Oligodendrocytes
Myotonic dystrophy type 1
DMPK
Male
Myostatin
Dystrophin
Cardiac muscle
GSK3
Gene editing
Myotonic Dystrophy Type 1
Autophagy
Dynamin 2
DMSXL mice
Acute coronary syndrome
Acetylcholinesterase knockout mouse
Dystrophie myotonique
Antisense oligonucleotides
CRISPR/Cas9
GABA
Astrocytes
Gene Therapy
Trinucleotide Repeat Expansion
Muscular dystrophy
Glutamate
Mice
Cell penetrating peptide
Cytoskeleton
Astrocyte
RNA splicing
CTG repeat contractions
Heart
Gene therapy
CTG repeats
Genotype phenotype correlation
Exercice
Myelin